Figure 5
(A–C) Scatter dot plots and arithmetic means ± SEM (n=6; arbitrary units, a.u.) of MSX2 (A), CBFA1 (B) and ALPL (C) relative mRNA expression in HAoSMCs following transfection with negative control siRNA (Neg.si) or SGK1 siRNA (SGK1si) and treatment for 24 h with control or bacterial sphingomyelinase (SMase). (D–F) Scatter dot plots and arithmetic means ± SEM (n=6; a.u.) of MSX2 (D), CBFA1 (E) and ALPL (F) relative mRNA expression in HAoSMCs following transfection with negative control siRNA (Neg.si) or SGK1 siRNA (SGK1si) and treatment for 24 h with control or C2-ceramide (C2-cer). *(P<0.05), **(P<0.01), ***(P<0.001) significant compared with Neg.si-transfected HAoSMCs; †(P<0.05), ††(P<0.01) significant compared with Negsi-transfected and SMase/C2-cer-treated HAoSMCs.
Silencing of SGK1 blunts ASM- and ceramide-induced osteo-/chondrogenic transdifferentiation of HAoSMCs

(A–C) Scatter dot plots and arithmetic means ± SEM (n=6; arbitrary units, a.u.) of MSX2 (A), CBFA1 (B) and ALPL (C) relative mRNA expression in HAoSMCs following transfection with negative control siRNA (Neg.si) or SGK1 siRNA (SGK1si) and treatment for 24 h with control or bacterial sphingomyelinase (SMase). (D–F) Scatter dot plots and arithmetic means ± SEM (n=6; a.u.) of MSX2 (D), CBFA1 (E) and ALPL (F) relative mRNA expression in HAoSMCs following transfection with negative control siRNA (Neg.si) or SGK1 siRNA (SGK1si) and treatment for 24 h with control or C2-ceramide (C2-cer). *(P<0.05), **(P<0.01), ***(P<0.001) significant compared with Neg.si-transfected HAoSMCs; †(P<0.05), ††(P<0.01) significant compared with Negsi-transfected and SMase/C2-cer-treated HAoSMCs.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept